Literature DB >> 31416500

[Clinical features and prognosis of children with acute lymphoblastic leukemia and different platelet levels].

Ao-Li Zhang1, Xiao-Juan Chen, Yao Zou, Wen-Yu Yang, Ye Guo, Shu-Chun Wang, Li Zhang, Xiao-Ming Liu, Min Ruan, Tian-Feng Liu, Ben-Quan Qi, Xiao-Fan Zhu.   

Abstract

OBJECTIVE: To study the association of platelet level at diagnosis with prognosis in children with acute lymphoblastic leukemia (ALL).
METHODS: A total of 892 children with ALL who underwent chemotherapy with the CCLG-ALL 2008 regimen were enrolled. According to the platelet count at diagnosis, these children were divided into normal platelet count group (platelet count ≥100×109/L; n=263) and thrombocytopenia group (platelet count <100×109/L; n=629). The thrombocytopenia group was further divided into (50- <100)×109/L (n=243), (20- <50)×109/L (n=263), and <20×109/L (n=123) subgroups. The association of clinical features (sex, age, immunophenotype, and molecular biology) with event-free survival (EFS) and overall survival (OS) was analyzed.
RESULTS: Compared with the thrombocytopenia group, the normal platelet count group had significantly lower positive rate of MLL gene rearrangement and recurrence rate (P<0.05), as well as a significantly higher 10-year EFS rate (P<0.05). There was no significant difference in 10-year OS between the two groups (P>0.05). The normal platelet count group still had a significantly higher 10-year EFS rate than the thrombocytopenia group after the children with MLL gene rearrangement were excluded (P<0.05), and there was still no significant difference in 10-year OS between the two groups (P>0.05). The <20×109/L subgroup had significantly lower 10-year EFS and OS rates than the normal platelet count group, the (50- <100)×109/L subgroup, and the (20- <50)×109/L subgroup (P<0.05). After the children with MLL gene rearrangement were excluded, the <20×109/L subgroup still had significantly lower 10-year EFS and OS rates than the normal platelet count group, the (50-<100)×109/L subgroup, and the (20- <50)×109/L subgroup (P<0.05).
CONCLUSIONS: ALL children with MLL gene rearrangement often have the clinical manifestation of thrombocytopenia. Platelet level at diagnosis is associated with the prognosis of ALL children. The children with normal platelet count have a low recurrence rate and good prognosis, and those with a platelet count of <20×109/L have the worst prognosis.

Entities:  

Mesh:

Year:  2019        PMID: 31416500      PMCID: PMC7389902     

Source DB:  PubMed          Journal:  Zhongguo Dang Dai Er Ke Za Zhi        ISSN: 1008-8830


  19 in total

Review 1.  Platelets and metastasis revisited: a novel fatty link.

Authors:  Gaorav P Gupta; Joan Massagué
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

Review 2.  MLL leukemia and future treatment strategies.

Authors:  Rolf Marschalek
Journal:  Arch Pharm (Weinheim)       Date:  2015-03-04       Impact factor: 3.751

3.  Childhood and adolescent cancer statistics, 2014.

Authors:  Elizabeth Ward; Carol DeSantis; Anthony Robbins; Betsy Kohler; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2014-01-31       Impact factor: 508.702

Review 4.  Transcriptional activation by MLL fusion proteins in leukemogenesis.

Authors:  Akihiko Yokoyama
Journal:  Exp Hematol       Date:  2016-11-16       Impact factor: 3.084

Review 5.  Acute lymphoblastic leukaemia.

Authors:  Hiroto Inaba; Mel Greaves; Charles G Mullighan
Journal:  Lancet       Date:  2013-03-22       Impact factor: 79.321

6.  Platelet changes in acute leukemia.

Authors:  Xu Qian; Liu Wen-jun
Journal:  Cell Biochem Biophys       Date:  2013       Impact factor: 2.194

Review 7.  PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma.

Authors:  Arne Ostman
Journal:  Cytokine Growth Factor Rev       Date:  2004-08       Impact factor: 7.638

8.  Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002.

Authors:  Jan Stary; Martin Zimmermann; Myriam Campbell; Luis Castillo; Eduardo Dibar; Svetlana Donska; Alejandro Gonzalez; Shai Izraeli; Dragana Janic; Janez Jazbec; Josip Konja; Emilia Kaiserova; Jerzy Kowalczyk; Gabor Kovacs; Chi-Kong Li; Edina Magyarosy; Alexander Popa; Batia Stark; Yahia Jabali; Jan Trka; Ondrej Hrusak; Hansjörg Riehm; Giuseppe Masera; Martin Schrappe
Journal:  J Clin Oncol       Date:  2013-12-16       Impact factor: 44.544

9.  Rearrangement of the MLL gene confers a poor prognosis in childhood acute lymphoblastic leukemia, regardless of presenting age.

Authors:  F G Behm; S C Raimondi; J L Frestedt; Q Liu; W M Crist; J R Downing; G K Rivera; J H Kersey; C H Pui
Journal:  Blood       Date:  1996-04-01       Impact factor: 22.113

10.  Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission.

Authors:  Stefan Faderl; Peter F Thall; Hagop M Kantarjian; Zeev Estrov
Journal:  Br J Haematol       Date:  2002-06       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.